金吾财讯 | 和铂医药(02142)尾盘走强，截至发稿，涨7.46%，报4.18港元，成交额2356万港元。消息面上，和铂医药公布，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。HBM9378/SKB378(现亦称WIN378)乃公司与科伦博泰开展的共同开发项目，二者共同享有大中华地区及多个东南亚及西亚国家的权利。HBM9378/SKB378是一款由两条重链及两条轻链(H2L2)平台产生的全人源单克隆抗体。该抗体针对胸腺基质淋巴细胞生成素(TSLP)，通过阻断该因子和受体的相互作用来抑制TSLP介导的信号通路，其较长的半衰期优化设计和优秀的理化性质使其在给药方面拥有优势。目前，公司已于中国完成了治疗中重度哮喘的INDI期试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.